DOCSLIB.ORG

Intrinsic Cardiomyopathy in Marfan Syndrome: Results from In-Vivo and Ex-Vivo Studies of the Fbn1c1039g/+ Model and Longitudinal Findings in Humans

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Intrinsic Cardiomyopathy in Marfan Syndrome: Results from In-Vivo and Ex-Vivo Studies of the Fbn1c1039g/+ Model and Longitudinal Findings in Humans nature publishing group Articles Translational Investigation Intrinsic cardiomyopathy in Marfan syndrome: results from in-vivo and ex-vivo studies of the Fbn1C1039G/+ model and longitudinal findings in humans Laurence Campens1, Marjolijn Renard1, Bram Trachet2, Patrick Segers2, Laura Muino Mosquera1, Johan De Sutter3, Lynn Sakai4, Anne De Paepe1 and Julie De Backer1 BACKGROUND: Mild intrinsic cardiomyopathy in patients Cardiovascular involvement in MFS is characterized by pro- with Marfan syndrome (MFS) has consistently been evi- gressive dilatation of the ascending aorta at the level of the denced by independent research groups. So far, little is known sinuses of Valsalva, ensuing a risk for type A aortic dissection about the long-term evolution and pathophysiology of or -rupture and aortic valve regurgitation (2). Other estab- this finding. lished cardiovascular manifestations of MFS include mitral METHODS: To gain more insights into the pathophysiology of valve prolapse and pulmonary artery dilatation. More recently, MFS-related cardiomyopathy, we performed in-vivo and ex-vivo several independent studies demonstrated the presence of— studies of 11 Fbn1C1039G/+ mice and 9 wild-type (WT) littermates. mostly subclinical—intrinsic cardiomyopathy (CMP) with Serial ultrasound findings obtained in mice were correlated to both left and right ventricular (LV and RV) systolic and dia- the human phenotype. We therefore reassessed left ventricular stolic dysfunction in MFS patients (3,4). The current know­ (LV) function parameters over a 6-y follow-up period in 19 pre- ledge of MFS-related CMP is based on cross-sectional studies, viously reported MFS patients, in whom we documented mild but little is known about the long-term evolution and patho- LV dysfunction. physiology of this finding. RESULTS: Fbn1C1039G/+ mice demonstrated LV contractile dys- To unravel the underlying pathophysiology of MFS-related function. Subsequent ex-vivo studies of the myocardium of CMP, the knowledge obtained from the study of other MFS adult mutant mice revealed upregulation of TGFβ-related manifestations may at least be partly translated to the cardiac pathways and consistent abnormalities of the microfibrillar phenotype. Upregulation of TGFβ signaling, with activation of network, implicating a role for microfibrils in the mechanical the canonical (SMAD2/3) and noncanonical (predominantly properties of the myocardium. Echocardiographic parameters ERK1/2) pathways, is implicated in aortic dilatation, mitral did not indicate clinical significant deterioration of LV function valve prolapse, pulmonary emphysema, and skeletal myopa- during follow-up in our patient cohort. thy (reviewed in ref. (5)). Interestingly, TGFβ upregulation CONCLUSION: In analogy with what is observed in the major- has been evidenced in hereditary CMP (dilated, hypertro- ity of MFS patients, the Fbn1C1039G/+ mouse model demonstrates phic, and arrhythmogenic right ventricular CMP), where it is mild intrinsic LV dysfunction. Both extracellular matrix and linked to cardiac interstitial fibrosis (6–10). In the Fbn1mgR/mgR molecular alterations are implicated in MFS-related cardiomy- model, which is a severe murine model for MFS demonstrat- opathy. This model may now enable us to study therapeutic ing dilated CMP from 2 mo of age, selective upregulation of interventions on the myocardium in MFS. the noncanonical signaling pathway was evidenced (11). In addition to its role as a regulator of TGFβ bioavailability, fibrillin-1 has an important structural role, providing stability arfan syndrome (MFS, GenBank accession nos. L13923) and elasticity to tissues. Structural dysfunction is implicated Mis an autosomal dominant inherited connective tissue in several MFS manifestations including lens luxation and disorder caused by mutations in the fibrillin-1 gene (FBN1) aortic dilatation (12). Additionally, loss of mechanical prop- encoding the extracellular matrix protein fibrillin-1. The clini- erties of the microfibrillar network in the myocardium may cal diagnosis of MFS relies on the identification of characteristic evoke ventricular dysfunction (11–13). Another mechanism clinical manifestations, mainly occurring in the cardiovascu- through which aberrant microfibrils could lead to contractile lar, musculoskeletal, and ocular system, as summarized in the dysfunction of the myocardium, is through loss of binding to ‘‘Revised Ghent Nosology’’, and may be supplemented by the integrin receptors, which play a key role in cell-matrix interac- identification of a causal FBN1 mutation (1). tions (extracellular matrix (ECM)) and mechanotransduction 1Center for Medical Genetics Ghent, Ghent University Hospital, Ghent, Belgium; 2IBiTech-bioMMeda, Ghent University, Ghent, Belgium; 3Internal Medicine, Ghent University, Ghent, Belgium; 4Shriners Hospital for Children, Oregon Health & Science University, Portland, Oregon. Correspondence: Laurence Campens ([email protected]) Received 16 November 2014; accepted 3 March 2015; advance online publication 1 July 2015. doi:10.1038/pr.2015.110 256 Pediatric ReseArcH Volume 78 | Number 3 | September 2015 Copyright © 2015 International Pediatric Research Foundation, Inc. Marfan-related cardiomyopathy Articles across the cell surface through the cytoskeleton (14–16). This developed significant aortic valve regurgitation with holodia- hypothesis is supported by the observation that disruption stolic flow reversal in the descending aorta; in one of them this of the integrin pathway leads to the development of CMP was already apparent on the scan at 6 mo. None of the WT in both mice and humans (17–19). Interestingly, the down- mice presented significant aortic valve dysfunction. After 12 stream integrin pathway is downregulated in the myocardium mo, two additional MFS mice died, one of dissection at 60 wk, of the Fbn1mgR/mgR model (11). the other died shortly after the last scan and demonstrated The objective of the current study is to gain more insight into no evidence for aortic dissection or internal hemorrhage on the underlying pathophysiology of MFS-related CMP. To this necropsy. aim, we first performed longitudinal ultrasound studies using LV fractional shortening was lower in MFS mice at all time a representative and well-characterized murine model for points with significantly lower values at 6 mo (30.9% ± 7.9) MFS, the Fbn1C1039G/+ model, and compared our findings to the vs. 41.2% ± 3.0; P = 0.001) (Figure 1). From 6 mo onward, human cardiac phenotype. Subsequently, we explored struc- fractional shortening remained stable (31.6% ± 5.5 at 12 mo, tural and molecular alterations in the mouse myocardium. P = 0.71). Heart rate, weight, sex, sinus diameter, and aortic regurgitation were not identified as confounding factors of LV RESULTS fractional shortening with univariate regression analysis (P = Serial Ultrasound Data in the Fbn1C1039G/+ Mouse Model 0.61, P = 0.99, P = 0.53, P = 0.68, and P = 0.81, respectively). Although there was a nonsignificant trend toward larger aortic We found no differences in diastolic function between MFS diameters at 1 and 3 mo, aortic diameters in the Fbn1C1039G/+ and WT mice (Table 1). mice were only significantly increased from month 6 onward when compared to wild-type (WT) mice. Aortic dilatation Clinical Studies extended from the sinuses of Valsalva to the ascending and Impaired ventricular function has been established in humans transverse aorta (Table 1)—which is different from the human (3,4), but so far, no data on evolutionary changes have been aortic phenotype being limited to the level of the aortic sinus reported. In view of our results obtained in mice, we aimed to in most cases. Main pulmonary artery diameters were not sig- provide longitudinal human data for which we analyzed echo- nificantly different between both groups. During follow-up, cardiographic studies at different time-points available from two MFS mice died of aortic dissection at 47 and 48 wk of age; our MFS patient population. An initial detailed study of left on their scan at 6 mo they exhibited severe aortic dilatation ventricular function in this population indicated mild intrinsic associated with significant aortic valve regurgitation. At the LV systolic and diastolic dysfunction (20). Data obtained from end of the follow-up period, three additional MFS mice had the subsequent preliminary retrospective analysis demonstrate stable LV dimensions and no clinically significant decline of Table 1. Echocardiographic parameters of Fbn1C1039G/+ mice at 12 mo LV systolic or diastolic function (Table 2). Two patients devel- of age oped moderate valvular dysfunction upon follow-up (one WT MFS patient with aortic and one with mitral valve dysfunction) N = 9 N = 9 P value Females 4 (44%) 6 (66%) 0.64 50 Weight (kg) 27.7 ± 3.4 26.2 ± 4.7 0.34 ** HR (bpm) 423.8 ± 19.1 425.8 ± 27.0 0.95 40 Aortic diameters Sinus (mm) 1.9 ± 0.2 2.6 ± 0.5 0.003 30 Ascending aorta (mm) 1.7 ± 0.2 2.3 ± 0.7 0.014 Arch (mm) 1.4 ± 0.1 1.8 ± 0.2 0.006 20 Descending aorta (mm) 1.2 ± 0.1 1.3 ± 0.2 0.014 Main pulmonary artery (mm) 1.4 ± 0.2 1.6 ± 0.3 0.38 Fractional shortening (FS; %) 10 LVEDD (mm) 3.7 ± 0.4 3.7 ± 0.7 1.0 LVESD (mm) 2.1 ± 0.2 2.5 ± 0.5 0.063 0 FS (%) 42.0 ± 6.3 31.6 ± 5.5 0.011 13612 E/A 1.4 ± 0.4 1.1 ± 0.2 0.14 Age (mo) DT (ms) 14.9 ± 3.7 17.7 ± 7.1 0.74 Figure 1. Bar chart with error bars (representing 1 standard error) of left C1039G/+ Em (mm/s) 21.4 ± 8.2 23.9 ± 11.1 0.73 ventricular fractional shortening of 11 Fbn1 and 9 wild-type (WT) mice at 1, 3, and 6 mo and in 9 Fbn1C1039G/+ and 9 WT mice at 12 mo of age. E/E 37.1 ± 23.7 23.4 ± 5.8 0.20 m Fbn1C1039G/+ mice demonstrate significant lower fractional shortening from DT, deceleration time; FS, fractional shortening; HR, heart rate; LVEDD, left ventricular 6 mo of age on in comparison to WT mice. White bars represent WT mice end diastolic diameter; LVESD, left ventricular end systolic diameter; MFS, Marfan and black bars Fbn1C1039G/+ mice.
Load more

Recommended publications
  • Marfan Syndrome
    Marfan syndrome Description Marfan syndrome is a disorder that affects the connective tissue in many parts of the body. Connective tissue provides strength and flexibility to structures such as bones, ligaments, muscles, blood vessels, and heart valves. The signs and symptoms of Marfan syndrome vary widely in severity, timing of onset, and rate of progression. Because connective tissue is found throughout the body, Marfan syndrome can affect many systems, often causing abnormalities in the heart, blood vessels, eyes, bones, and joints. The two primary features of Marfan syndrome are vision problems caused by a dislocated lens (ectopia lentis) in one or both eyes and defects in the large blood vessel that distributes blood from the heart to the rest of the body (the aorta). The aorta can weaken and stretch, which may lead to a bulge in the blood vessel wall (an aneurysm). Stretching of the aorta may cause the aortic valve to leak, which can lead to a sudden tearing of the layers in the aorta wall (aortic dissection). Aortic aneurysm and dissection can be life threatening. Many people with Marfan syndrome have additional heart problems including a leak in the valve that connects two of the four chambers of the heart (mitral valve prolapse) or the valve that regulates blood flow from the heart into the aorta (aortic valve regurgitation). Leaks in these valves can cause shortness of breath, fatigue, and an irregular heartbeat felt as skipped or extra beats (palpitations). Individuals with Marfan syndrome are usually tall and slender, have elongated fingers and toes (arachnodactyly), loose joints, and have an arm span that exceeds their body height.
    [Show full text]
  • Mutation in Genes FBN1, AKT1, and LMNA: Marfan Syndrome, Proteus Syndrome, and Progeria Share Common Systemic Involvement
    Review Mutation in Genes FBN1, AKT1, and LMNA: Marfan Syndrome, Proteus Syndrome, and Progeria Share Common Systemic Involvement Tonmoy Biswas.1 Abstract Genetic mutations are becoming more deleterious day by day. Mutations of Genes named FBN1, AKT1, LMNA result specific protein malfunction that in turn commonly cause Marfan syndrome, Proteus syndrome, and Progeria, respectively. Articles about these conditions have been reviewed in PubMed and Google scholar with a view to finding relevant clinical features. Precise keywords have been used in search for systemic involvement of FBN1, AKT1, and LMNA gene mutations. It has been found that Marfan syndrome, Proteus syndrome, and Progeria commonly affected musculo-skeletal system, cardiovascular system, eye, and nervous system. Not only all of them shared identical systemic involvement, but also caused several very specific anomalies in various parts of the body. In spite of having some individual signs and symptoms, the mutual manifestations were worth mentio- ning. Moreover, all the features of the mutations of all three responsible genes had been co-related and systemically mentioned in this review. There can be some mutual properties of the genes FBN1, AKT1, and LMNA or in their corresponding proteins that result in the same presentations. This study may progress vision of knowledge regarding risk factors, patho-physiology, and management of these conditions, and relation to other mutations. Keywords: Genetic mutation; Marfan syndrome; Proteus syndrome; Progeria; Gene FBN1; Gene AKT1; Gene LMNA; Musculo-skeletal system; Cardiovascular system; Eye; Nervous system (Source: MeSH, NLM). Introduction Records in human mutation databases are increasing day by 5 About the author: Tonmoy The haploid human genome consists of 3 billion nucleotides day.
    [Show full text]
  • Genetic Determinants Underlying Rare Diseases Identified Using Next-Generation Sequencing Technologies
    Western University Scholarship@Western Electronic Thesis and Dissertation Repository 8-2-2018 1:30 PM Genetic determinants underlying rare diseases identified using next-generation sequencing technologies Rosettia Ho The University of Western Ontario Supervisor Hegele, Robert A. The University of Western Ontario Graduate Program in Biochemistry A thesis submitted in partial fulfillment of the equirr ements for the degree in Master of Science © Rosettia Ho 2018 Follow this and additional works at: https://ir.lib.uwo.ca/etd Part of the Medical Genetics Commons Recommended Citation Ho, Rosettia, "Genetic determinants underlying rare diseases identified using next-generation sequencing technologies" (2018). Electronic Thesis and Dissertation Repository. 5497. https://ir.lib.uwo.ca/etd/5497 This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of Scholarship@Western. For more information, please contact [email protected]. Abstract Rare disorders affect less than one in 2000 individuals, placing a huge burden on individuals, families and the health care system. Gene discovery is the starting point in understanding the molecular mechanisms underlying these diseases. The advent of next- generation sequencing has accelerated discovery of disease-causing genetic variants and is showing numerous benefits for research and medicine. I describe the application of next-generation sequencing, namely LipidSeq™ ‒ a targeted resequencing panel for the identification of dyslipidemia-associated variants ‒ and whole-exome sequencing, to identify genetic determinants of several rare diseases. Utilization of next-generation sequencing plus associated bioinformatics led to the discovery of disease-associated variants for 71 patients with lipodystrophy, two with early-onset obesity, and families with brachydactyly, cerebral atrophy, microcephaly-ichthyosis, and widow’s peak syndrome.
    [Show full text]
  • Orthopedic-Conditions-Treated.Pdf
    Orthopedic and Orthopedic Surgery Conditions Treated Accessory navicular bone Achondroplasia ACL injury Acromioclavicular (AC) joint Acromioclavicular (AC) joint Adamantinoma arthritis sprain Aneurysmal bone cyst Angiosarcoma Ankle arthritis Apophysitis Arthrogryposis Aseptic necrosis Askin tumor Avascular necrosis Benign bone tumor Biceps tear Biceps tendinitis Blount’s disease Bone cancer Bone metastasis Bowlegged deformity Brachial plexus injury Brittle bone disease Broken ankle/broken foot Broken arm Broken collarbone Broken leg Broken wrist/broken hand Bunions Carpal tunnel syndrome Cavovarus foot deformity Cavus foot Cerebral palsy Cervical myelopathy Cervical radiculopathy Charcot-Marie-Tooth disease Chondrosarcoma Chordoma Chronic regional multifocal osteomyelitis Clubfoot Congenital hand deformities Congenital myasthenic syndromes Congenital pseudoarthrosis Contractures Desmoid tumors Discoid meniscus Dislocated elbow Dislocated shoulder Dislocation Dislocation – hip Dislocation – knee Dupuytren's contracture Early-onset scoliosis Ehlers-Danlos syndrome Elbow fracture Elbow impingement Elbow instability Elbow loose body Eosinophilic granuloma Epiphyseal dysplasia Ewing sarcoma Extra finger/toes Failed total hip replacement Failed total knee replacement Femoral nonunion Fibrosarcoma Fibrous dysplasia Fibular hemimelia Flatfeet Foot deformities Foot injuries Ganglion cyst Genu valgum Genu varum Giant cell tumor Golfer's elbow Gorham’s disease Growth plate arrest Growth plate fractures Hammertoe and mallet toe Heel cord contracture
    [Show full text]
  • Paradoxical Aortic Stiffening and Subsequent Cardiac Dysfunction in Hutchinson-Gilford Progeria Syndrome
    bioRxiv preprint doi: https://doi.org/10.1101/790477; this version posted October 2, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Paradoxical Aortic Stiffening and Subsequent Cardiac Dysfunction in Hutchinson‐Gilford Progeria Syndrome S‐I. Murtada1, Y. Kawamura1, A.W. Caulk1, H. Amadzadeh1, N. Mikush2, K. Zimmerman3, D. Kavanagh3, D. Weiss1, M. Latorre1, Z.W. Zhang4, G.S. Shadel5, D.T. Braddock3, J.D. Humphrey1,6 1Department of Biomedical Engineering Yale University, New Haven, CT, USA 2Translational Research Imaging Center, 3Department of Pathology, 4Section of Cardiovascular Medicine, and 6Vascular Biology and Therapeutics Program Yale School of Medicine, New Haven, CT, USA 5Molecular and Cellular Biology Salk Institute for Biological Studies, La Jolla, CA, USA Address for Correspondence: J.D. Humphrey, Ph.D. Department of Biomedical Engineering Yale University, New Haven, CT 06520 USA +1‐203‐432‐6428 [email protected] Running Title: Aortic Stiffening in late‐stage Progeria Keywords: progeria, aortic stiffness, pulse wave velocity, diastolic dysfunction, allometric scaling, aging 1 bioRxiv preprint doi: https://doi.org/10.1101/790477; this version posted October 2, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. SUMMARY Hutchinson‐Gilford Progeria Syndrome (HGPS) is an ultra‐rare disorder with devastating sequelae resulting in early death, presently believed to stem primarily from heart failure secondary to central arterial stiffening. We analyze novel longitudinal cardiovascular data from a mouse model of HGPS (LmnaG609G/G609G) using allometric scaling and advanced computational modelling and show that a late‐stage increase in pulse wave velocity, with associated diastolic dysfunction but preserved systolic function, emerges with a loss of aortic function, independent of sex.
    [Show full text]
  • Cardiomyopathy in Patients with Marfan Syndrome and Marfanoid Habitus
    ORIGINAL ARTICLE Cardiomyopathy in patients with Marfan syndrome and marfanoid habitus Ekaterina Luneva MD, PhD1, Eduard Malev MD, PhD1,2, Alexandra Korshunova MD1,2, Svetlana Reeva MD PhD1,2, Eugeniy Timofeev MD PhD1,2 and Eduard Zemtsovsky Prof MD PhD1,2 Lunev E, Malev E, Korshunova A, et al. Cardiomyopathy in patients with worsening was detected in MS group comparing to control group. In marfanoid Marfan syndrome and marfanoid habitus. Curr Res Cardiol 2017;4(1): 9-13. habitus subjects, we found significant decrease of the circumferential strain in the interventricular septum and inferior wall. transforming growth factor-β1 OBJECTIVES: The term “Marfan cardiomyopathy” is used to indicate and -β2 serum levels were elevated in patients with Marfan syndrome. changes in left ventricular function in the absence of significant valvular Elevation of transforming growth factor-β1 was statistically nonsignificant pathology in Marfan syndrome. It is still unknown if there are any changes in unlike to transforming growth factor-β2 in the marfanoid habitus group. cardiac function in patients with similar connective tissue abnormality such Negative correlations between the serum level of transforming growth as marfanoid habitus. factor-β2 and systolic radial strain in the marfanoid habitus group also have been found. METHODS: In the study were included 98 persons - 8 patients with Marfan syndrome, 24 with marfanoid habitus and 66 healthy subjects. CONCLUSION: Worsening of regional myocardial deformation may be Echocardiography was performed to all patients. Speckle tracking the first sign of deterioration of the left ventricular systolic function and the echocardiography was used to assess the left ventricular deformation indices.
    [Show full text]
  • A Consensus Statement on the Surgical Treatment of Charcot
    FAIXXX10.1177/1071100720922220Foot & Ankle InternationalPfeffer et al 922220review-article2020 Current Concepts Review Foot & Ankle International® 2020, Vol. 41(7) 870 –880 A Consensus Statement on the Surgical © The Author(s) 2020 Article reuse guidelines: sagepub.com/journals-permissions Treatment of Charcot-Marie-Tooth Disease DOI:https://doi.org/10.1177/1071100720922220 10.1177/1071100720922220 journals.sagepub.com/home/fai Glenn B. Pfeffer, MD1, Tyler Gonzalez, MD, MBA2 , James Brodsky, MD3, John Campbell, MD4, Chris Coetzee, MD5 , Stephen Conti, MD6, Greg Guyton, MD7, David N. Herrmann, MBBCh8, Kenneth Hunt, MD9, Jeffrey Johnson, MD10 , William McGarvey, MD11, Michael Pinzur, MD12 , Steve Raikin, MD13, Bruce Sangeorzan, MD14, Alastair Younger, MD15, Max Michalski, MD1 , Tonya An, MD1 , and Naudereh Noori, MD1 Abstract Background: Charcot-Marie-Tooth (CMT) disease is a hereditary motor-sensory neuropathy that is often associated with a cavovarus foot deformity. Limited evidence exists for the orthopedic management of these patients. Our goal was to develop consensus guidelines based upon the clinical experiences and practices of an expert group of foot and ankle surgeons. Methods: Thirteen experienced, board-certified orthopedic foot and ankle surgeons and a neurologist specializing in CMT disease convened at a 1-day meeting. The group discussed clinical and surgical considerations based upon existing literature and individual experience. After extensive debate, conclusion statements were deemed “consensus” if 85% of the group were in agreement and “unanimous” if 100% were in support. Conclusions: The group defined consensus terminology, agreed upon standardized templates for history and physical examination, and recommended a comprehensive approach to surgery. Early in the course of the disease, an orthopedic foot and ankle surgeon should be part of the care team.
    [Show full text]
  • Familial Thoracic Aortic Aneurysms
    REVIEW CURRENT OPINION Familial thoracic aortic aneurysms Guillaume Jondeaua and Catherine Boileaub Purpose of review A lot of new data have been obtained in familial thoracic aortic aneurysms, including description of new entities and better understanding of pathophysiology. The aim of this review is to put them in perspective. Recent findings The new data have been collected, put together, and allowed a new classification scheme to be proposed by the Montalcino Aortic Consortium on the basis of the role of proteins coded by the culprit gene (either protein of the extracellular matrix or protein of the transforming growth factor-beta pathway, or protein of the contractile apparatus of the smooth muscle cell). These groups of diseases include aortic aneurysm, but the extent of extra-aortic vascular risk and the presence of extra-aortic (skeletal, ophthalmologic, neurological, or immunological) features vary according to the gene involved. This understanding also sheds light on the therapeutic benefits that can be foreseen for new molecules, or old molecules used in a newer way. Summary Classification of familial forms of thoracic aortic aneurysm should allow a better understanding of these diseases and therefore standardization of initial evaluation of the patients (vascular evaluation limited or not to the aorta, and extravascular evaluation, including or not skeleton, eyes, neurology, digestive tract, and immunological diseases) and individualization of therapy (adapted to both the genotype and the phenotype). Keywords aorta, Marfan, transforming growth factor-beta INTRODUCTION to be very low in patients with Marfan syndrome who undergo regular follow-up, take beta-blockers, Familial thoracic aortic aneurysms (TAA) represent & around 20% of all TAA.
    [Show full text]
  • The Skin in Genetically-Controlled Metabolic Disorders P
    Review Article J Med Genet: first published as 10.1136/jmg.10.2.101 on 1 June 1973. Downloaded from Journal of Medical Genetics (1973). 10, 101. The Skin in Genetically-controlled Metabolic Disorders P. C. H. NEWBOLD Department of Medicine, Cambridge University Medical School, Hills Road, Cambridge CB2 2QL Diseased nature oftentimes breaks forth however, it may lead to difficulty in assessing intelli- In strange eruptions.-Henry IV, part 1, III, i. gence, which is within normal range in 50% of The skin is now commonly accepted as a mirror patients. There is suggestive evidence of a re- of internal disease, but as with other looking-glasses, lationship between subnormal folate levels and low the evidence offered may be selected or ignored. intelligence (Carey et al, 1968), and studies have The epidermis is an interesting structure, especially shown increased turnover of folate coenzymes and rich in tyrosine, phenylalanine, tryptophan, and resulting folate depletion in these patients (Carey et histidine, when compared with the corium (Roth- al, 1968; Butterworth, Krumdieck, and Baugh, man, 1965). Tyrosinaemia and histidinaemia do 1971). There is also a high incidence of an organic not include cutaneous manifestations, but culture of brain syndrome following intracranial vascular skin fibroblasts is a helpful diagnostic tool for study- thromboses (Dunn, Perry, and Dolman, 1966), ing metabolic defects such as citrullinaemia, cysti- copyright. nosis, and maple-syrup urine disease (Scriver, 1969). Most of the conditions now to be described are rare, but if these metabolic diseases were com- mon, there could be no human race as we know it. Homocystinuria http://jmg.bmj.com/ This most informative anomaly was discovered during a study of mentally retarded patients in Ire- land (Carson and Neill, 1962).
    [Show full text]
  • Discover Dysplasias Gene Panel
    Discover Dysplasias Gene Panel Discover Dysplasias tests 109 genes associated with skeletal dysplasias. This list is gathered from various sources, is not designed to be comprehensive, and is provided for reference only. This list is not medical advice and should not be used to make any diagnosis. Refer to lab reports in connection with potential diagnoses. Some genes below may also be associated with non-skeletal dysplasia disorders; those non-skeletal dysplasia disorders are not included on this list. Skeletal Disorders Tested Gene Condition(s) Inheritance ACP5 Spondyloenchondrodysplasia with immune dysregulation (SED) AR ADAMTS10 Weill-Marchesani syndrome (WMS) AR AGPS Rhizomelic chondrodysplasia punctata type 3 (RCDP) AR ALPL Hypophosphatasia AD/AR ANKH Craniometaphyseal dysplasia (CMD) AD Mucopolysaccharidosis type VI (MPS VI), also known as Maroteaux-Lamy ARSB syndrome AR ARSE Chondrodysplasia punctata XLR Spondyloepimetaphyseal dysplasia with joint laxity type 1 (SEMDJL1) B3GALT6 Ehlers-Danlos syndrome progeroid type 2 (EDSP2) AR Multiple joint dislocations, short stature and craniofacial dysmorphism with B3GAT3 or without congenital heart defects (JDSCD) AR Spondyloepimetaphyseal dysplasia (SEMD) Thoracic aortic aneurysm and dissection (TADD), with or without additional BGN features, also known as Meester-Loeys syndrome XL Short stature, facial dysmorphism, and skeletal anomalies with or without BMP2 cardiac anomalies AD Acromesomelic dysplasia AR Brachydactyly type A2 AD BMPR1B Brachydactyly type A1 AD Desbuquois dysplasia CANT1 Multiple epiphyseal dysplasia (MED) AR CDC45 Meier-Gorlin syndrome AR This list is gathered from various sources, is not designed to be comprehensive, and is provided for reference only. This list is not medical advice and should not be used to make any diagnosis.
    [Show full text]
  • PHYSICAL ACTIVITY GUIDELINES Everyone —Including PEOPLE with MARFAN Syndrome— Benefits from Exercise
    NOV 2017 PHYSICAL ACTIVITY GUIDELINES EVERyONE —iNCLuDiNg PEOPLE WiTh MARFAN SyNDROME— BENEFiTS FROM ExERCiSE. Regular exercise improves both physical and emotional well-being and can be incorporated safely into the routine of people with Marfan syndrome. Therefore, they are encouraged to adapt health measures that protect them from Marfan features that can worsen and from medical conditions that are simply part of the aging process. With an early diagnosis, treatment , and lifestyle adaptations, many people with Marfan syndrome can now expect to live a normal life span. These guidelines are intended for those with Marfan syndrome and related disorders, however, individuals may have unique disease-specific manifestations that require additional consideration and restrictions. For example, those with Loeys Dietz syndrome may have cervical instability, which impacts guidelines on certain exercise and physical activity. Please consult with your physician about your individual case. WHY DOES PHYSICAL ACTIVITY HAVE TO BE MODIFIED FOR PEOPLE WITH MARFAN SYNDROME ? Marfan syndrome is a disorder of connective tissue. Connective tissue holds all parts of the body together and helps control how the body grows. Because connective tissue is found throughout the body, Marfan syndrome features can occur in many different parts of the body, including the heart, blood vessels, bones, joints, and eyes. Sometimes, the lungs and skin are also affected. Anyone with a health concern should learn about self care for their condition. An important part of self care is physical activity. Physical activity guidelines are important because they enable people to achieve the benefits of safe levels of exercise and, at the same time, ensure that they don’t add to medical problems related to Marfan syndrome.
    [Show full text]
  • Rev. 6/98 Chapter 2—Instructions for Completing a Certificate of Birth 1
    Instructions for Completing a Certificate of Birth Chapter 2 Complete only one original Certificate of Birth (VS-111 or VS-111.1) and file the certificate with the local registrar. Use the current forms prescribed by the State Registrar and the Texas Department of Health. All entries should be completed, in blue or black ink, by the same printer or typewriter whenever possible. Typewritten additions to computer generated certificates can appear as alterations and cause future complications to the individuals presenting copies of their certificates. We discourage handwritten certificates; if no alternative is available, the certificate must be printed legibly in durable blue or black ink. Signatures must be written in durable blue or black ink. [HSC §191.025(d)] Hospitals using Certificate Manager may apply for approval to file the “short form” birth certificate, VS-111.1 (See Appendix B). This certificate consists of only the upper portion of the birth certificate, through item 21. The medical and health information, items 22 through 38, are reported electronically to the Bureau of Vital Statistics. The following requirements must be met for hospitals to use the “short form”: < the facility must use Certificate Manager software provided by TDH; < the facility must obtain all information required by the long certificate, VS-111; and < the facility must electronically transmit the complete birth certificate information to TDH no later than the seventh calendar day after the date of birth. [TAC §181.13(c)] For further information about Certificate Manager or to apply for approval to use the “short form” certificate, contact the BVS Records Receiving Program at (512) 458-7368.
    [Show full text]